Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Limonene for MAFLD
NCT04853082Phase 1Completed
- Start
- Feb 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic associated fatty liver disease (MAFLD) comparing Limonene with Placebo (2 arms). Primary endpoints: Controlled Attenuation Parameter at 12 weeks and Body Mass Index Rate at 12 weeks. Started Feb 2021; status: completed.
02
Drugs
Limonene
03
Conditions
metabolic associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT04853082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04853082.